These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 18819144)
21. Direct stenting in the DES era: Can we do better? Bass TA Catheter Cardiovasc Interv; 2007 Oct; 70(4):513-4. PubMed ID: 17896409 [No Abstract] [Full Text] [Related]
22. One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. Nakazawa G; Vorpahl M; Finn AV; Narula J; Virmani R JACC Cardiovasc Imaging; 2009 May; 2(5):625-8. PubMed ID: 19442951 [No Abstract] [Full Text] [Related]
23. NEVO™: a new generation of sirolimus-eluting coronary stent. Falotico R; Parker T; Grishaber R; Price S; Cohen SA; Rogers C EuroIntervention; 2009 Dec; 5 Suppl F():F88-93. PubMed ID: 22100684 [No Abstract] [Full Text] [Related]
24. A critical appraisal of the Janus carbostent. Kornowski R Catheter Cardiovasc Interv; 2009 Feb; 73(2):249-50. PubMed ID: 19156897 [No Abstract] [Full Text] [Related]
25. The artisan approach for stenting bifurcation lesions. Colombo A; Latib A JACC Cardiovasc Interv; 2010 Jan; 3(1):66-7. PubMed ID: 20129571 [No Abstract] [Full Text] [Related]
29. "Crying fire in a theater" or a "confirmatory sighting?". Ellis SG J Am Coll Cardiol; 2007 Jul; 50(3):268-9. PubMed ID: 17631220 [No Abstract] [Full Text] [Related]
30. Optical coherence tomography to diagnose under-expansion of a drug-eluting stent. Motreff P; Souteyrand G JACC Cardiovasc Imaging; 2009 Feb; 2(2):245-6; author reply 246. PubMed ID: 19356563 [No Abstract] [Full Text] [Related]
31. The gender paradox. Presbitero P EuroIntervention; 2009 Jan; 4(4):415, 417. PubMed ID: 19284061 [No Abstract] [Full Text] [Related]
32. Temporal course of neointimal formation after drug-eluting stent placement: is our understanding of restenosis changing? Finn AV; Nakazawa G; Kolodgie FD; Virmani R JACC Cardiovasc Interv; 2009 Apr; 2(4):300-2. PubMed ID: 19463440 [No Abstract] [Full Text] [Related]
33. The process of bringing new drug-eluting stents to market will they see the light of day? Holmes DR; Patel M JACC Cardiovasc Interv; 2008 Oct; 1(5):533-4. PubMed ID: 19463355 [No Abstract] [Full Text] [Related]
34. A ticking time bomb?: a case report of very late stent thrombosis more than 2 years after fracture of a Cypher stent. Ong SH; Mueller R; Boekstegers P Clin Res Cardiol; 2011 Oct; 100(10):951-3. PubMed ID: 21725857 [No Abstract] [Full Text] [Related]
35. Unfavorable bioresorbable vascular scaffold resorption, a cause of restenosis? Ishida K; Giacchi G; Brugaletta S; García-Álvarez A; Sabaté M Cardiovasc Revasc Med; 2016 Dec; 17(8):571-573. PubMed ID: 27345841 [TBL] [Abstract][Full Text] [Related]
36. Another small step for small vessels. Morrison DA Catheter Cardiovasc Interv; 2010 Jul; 76(1):67-9. PubMed ID: 20578195 [No Abstract] [Full Text] [Related]
38. A randomized comparison of sirolimus-eluting versus bare metal stents in the treatment of diabetic patients with native coronary artery lesions: the DECODE study. Chan C; Zambahari R; Kaul U; Lau CP; Whitworth H; Cohen S; Buchbinder M; Catheter Cardiovasc Interv; 2008 Nov; 72(5):591-600. PubMed ID: 18949772 [TBL] [Abstract][Full Text] [Related]
39. Observational studies of drug-eluting stents--some are more equal than others. Austin D; Oldroyd KG; Pell JP EuroIntervention; 2009 Jan; 4(4):419, 421, 423. PubMed ID: 19284062 [No Abstract] [Full Text] [Related]
40. Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting. Chacko R; Mulhearn M; Novack V; Novack L; Mauri L; Cohen SA; Moses J; Leon MB; Cutlip DE JACC Cardiovasc Interv; 2009 Jun; 2(6):498-503. PubMed ID: 19539252 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]